Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens

In newly diagnosed acute myeloid leukemia, immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pre-therapeutic risk factors. We explored the impact of time from diagnosis to treatment on outcomes in newly diagn...

詳細記述

書誌詳細

主要な著者:	David Baden, Sven Zukunft, Gema Hernandez, Nadine Wolgast, Sophie Steinhauser, Alexander Pohlmann, Christoph Schliemann, Jan-Henrik Mikesch, Bjorn Steffen, Tim Sauer, Maher Hanoun, Kerstin Schafer-Eckart, Stefan W. Krause, Mathias Hanel, Hermann Einsele, Edgar Jost, Tim H. Brummendorf, Sebastian Scholl, Andreas Hochhaus, Andreas Neubauer, Andreas Burchert, Martin Kaufmann, Dirk Niemann, Markus Schaich, Wolfgang Blau, Alexander Kiani, Martin Gorner, Ulrich Kaiser, Johannes Kullmer, Thomas Weber, Wolfgang E Berdel, Gerhard Ehninger, Carsten Muller-Tidow, Uwe Platzbecker, Hubert Serve, Martin Bornhauser, Christoph Rollig, Claudia D Baldus, Lars Fransecky
フォーマット:	Artigo
言語:	Inglês
出版事項:	Ferrata Storti Foundation 2024-04-01
シリーズ:	Haematologica
オンライン･アクセス:	https://haematologica.org/article/view/11564
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!